Mounjaro contains tirzepatide, which activates GIP and GLP-1 receptors. Ozempic contains semaglutide, which activates GLP-1 receptors. Both have uses in type 2 diabetes, but their exact indications, formulations, administration instructions, and evidence differ. Neither is automatically the best option for every patient. Start with the specific product and the health condition being treated, then compare the evidence that actually applies. Mounjaro prescribing information; Ozempic injection label
One naming detail matters in 2026: the current U.S. labeling includes Ozempic tablets as well as injection. A study comparing weekly injections does not directly compare Mounjaro with an Ozempic pill. This guide identifies the formulation each time. Our oral GLP-1 guide explains the broader formulation distinctions.
Mounjaro and Ozempic at a glance
| Comparison | Mounjaro | Ozempic |
|---|---|---|
| Active ingredient | Tirzepatide | Semaglutide |
| Receptor activity | GIP and GLP-1 receptor agonist | GLP-1 receptor agonist |
| Administration in the head-to-head study below (the label names the comparator as injected semaglutide) | Weekly subcutaneous injection | Weekly subcutaneous injection |
| Oral formulation in current U.S. labeling | No oral Mounjaro formulation in this label | Ozempic tablets have separate daily instructions |
| A central prescribing question | Does the exact labeled use fit this patient's condition? | Which formulation and labeled use fit this patient's condition? |
The comparison comes from the current prescribing information, including each medicine's mechanism and administration sections. The number of receptors a medicine activates is not itself a patient-level prediction of results or tolerability. Mounjaro, sections 2 and 12.1; Ozempic injection, sections 2 and 12.1; Ozempic tablets, section 2
What is each medicine approved to treat?
The Mounjaro label revised August 2026 includes improving glycemic control alongside diet and exercise in adults and children aged 10 years and older with type 2 diabetes. It also includes reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk of these events. Mounjaro, section 1
The Ozempic injection label includes improving glycemic control in adults with type 2 diabetes, reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and reducing the risk of sustained eGFR decline (a lasting fall in a measure of kidney function), end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. These are particular populations, not interchangeable claims. Ozempic injection, section 1
The Ozempic tablet label has its own indications: adult type 2 diabetes glycemic control and reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk. Do not automatically transfer every injection indication to the tablet. Ozempic tablets, section 1
Neither the Mounjaro label nor either Ozempic label lists weight management as an approved use. If your main question is treatment for obesity, ask which exact product is approved for your situation. This comparison does not turn either brand's diabetes indication into an obesity indication. Our Zepbound versus Mounjaro guide explains why the brand and indication both matter.
What did the head-to-head injection study find?
SURPASS-2 randomized 1,879 adults with type 2 diabetes whose glucose was inadequately controlled with stable metformin alone. It compared three once-weekly tirzepatide dose groups with one once-weekly injected semaglutide dose group over 40 weeks; the exact studied doses are listed in Table 5 of the Mounjaro label. It was open-label, with blinding for Mounjaro dose assignment. Mounjaro label, section 14.3, Table 5
In the label's Table 5, average reductions in HbA1c and in body weight at week 40 were larger in each of the three tirzepatide groups than in the semaglutide group, with the largest differences in the highest-dose tirzepatide group. These results describe the FDA-approved product in its trials; they do not describe compounded preparations. These group averages at a defined endpoint are adjusted least-squares estimates from the label’s modified intent-to-treat analysis of 1,876 participants who received at least one study dose, with specified enrollment-related exclusions, not a promised response for an individual. Missing week-40 data were handled using multiple imputation with retrieved dropout; the August 2026 Mounjaro label reports that 4–5% of participants across groups were missing the HbA1c endpoint. Table 5
The trial did not compare tirzepatide with the higher Ozempic injection dose that the current label also allows, an Ozempic tablet, or an obesity-dose semaglutide regimen. It also was not a trial of people without diabetes. Those gaps matter: “better in this comparison” cannot become “best for everyone” or a prediction of long-term cardiovascular outcomes.
How do safety and daily life enter the decision?
Both injection labels carry a boxed warning about thyroid C-cell tumors observed in rodents; whether this risk occurs in humans is unknown. The Ozempic tablet label carries the same boxed warning. Both injection labels contraindicate use in people with a personal or family history of medullary thyroid carcinoma, in people who have MEN 2, and in people who have had a serious hypersensitivity reaction to the medicine or its ingredients. Both also describe gastrointestinal effects and other important risks, including pancreatitis, dehydration-related kidney injury, and low blood sugar when used with insulin or an insulin secretagogue such as a sulfonylurea. A short comparison is not the complete safety information. Mounjaro, sections 4–6; Ozempic injection, sections 4–6
The two Medication Guides give the same urgent instructions for several of these risks. Stop the medicine and call your healthcare provider right away for severe pain in the stomach area that will not go away, with or without vomiting, because it can be a sign of pancreatitis. Stop the medicine and get medical help right away for signs of a serious allergic reaction, such as swelling of the face, lips, tongue, or throat, or problems breathing or swallowing. Tell your healthcare provider right away about nausea, vomiting, or diarrhea that does not go away, because the fluid loss can lead to kidney problems. These are not all the possible warning signs; read the Medication Guide supplied with your medicine. Mounjaro Medication Guide; Ozempic injection Medication Guide
Two differences between the labels are easy to miss. The Mounjaro Medication Guide says birth control pills taken by mouth may not work as well while using Mounjaro, and a healthcare provider may recommend another type of birth control for 4 weeks after starting and for 4 weeks after each dose increase. The Ozempic injection label says to stop Ozempic at least 2 months before a planned pregnancy. Mounjaro Medication Guide; Ozempic injection, section 8.3
Before starting either medicine, tell your prescriber about past pancreas problems such as pancreatitis, other medicines, eye disease, severe stomach problems such as slowed stomach emptying (gastroparesis), pregnancy plans, breastfeeding, and upcoming procedures involving anesthesia. The exact label and your clinical circumstances determine what needs closer review. Do not switch, combine, or convert doses yourself.
Bring this decision worksheet to your appointment
| Decision area | A concrete question to answer |
|---|---|
| Treatment goal | Are we treating type 2 diabetes, a specific cardiovascular or kidney risk, obesity, or more than one condition? |
| Applicable evidence | Which product, dose, population, and outcome support this choice for me? |
| Tolerability and interactions | Which parts of my history and medication list change the benefit–risk discussion? |
| Practical use | Which exact device or tablet instructions can I reliably follow? |
| Access and follow-up | What are the pharmacy cost, coverage requirements, monitoring plan, and reassessment date? |
The most useful comparison ends with a documented plan that fits the patient, not a brand declared the winner. For the affordability discussion, compare current pharmacy quotes for the exact prescriptions. Our Ozempic cost guide explains why an advertised minimum and your next pharmacy bill can differ.
Educational information for adults, not an individual treatment plan or a recommendation of either medicine. Sources retrieved and checked October 27, 2026. Mounjaro is a registered trademark of Eli Lilly and Company. Ozempic and Rybelsus are registered trademarks of Novo Nordisk A/S. Eli Lilly and Company and Novo Nordisk are not affiliated with and do not endorse Majesta Health. Majesta Health does not sell Mounjaro, Ozempic or Rybelsus.
Frequently Asked Questions
Is Mounjaro the same as Ozempic?
No. Mounjaro contains tirzepatide; Ozempic contains semaglutide. They differ in receptor activity, labeling, formulations, and administration instructions. They are not milligram-for-milligram substitutes.
Did Mounjaro lead to more weight reduction than injected semaglutide in the head-to-head diabetes study?
In SURPASS-2, a 40-week study of adults with type 2 diabetes whose blood sugar was inadequately controlled on metformin alone, average body-weight reductions were larger with each studied Mounjaro dose than with the single studied dose of injected semaglutide. These results describe the FDA-approved product in its trials; they do not describe compounded preparations. These are group averages, not a prediction or promise for any one person. Weight reduction is not among the approved uses listed in section 1 of the Mounjaro label or either Ozempic label. The study did not compare every dose or formulation, people without diabetes, or long-term outcomes. Source: Mounjaro prescribing information, section 14.3, Table 5.
Is Ozempic still only an injection?
No. Current U.S. labeling includes Ozempic tablets, in a label shared with Rybelsus that is separate from the Ozempic injection label. Their directions and evidence must be evaluated separately from the weekly injection. Source: Rybelsus and Ozempic tablets prescribing information, sections 1 and 2.
Can I switch from one to the other?
That requires a prescriber's plan. The medicines have different dose schedules and product-specific considerations. Do not infer a starting dose from a comparison chart or reuse the other product's instructions.
Sources
This article is based on the following primary sources. Links open the original documents.
- 1.Eli Lilly and Company. Mounjaro (tirzepatide) injection, U.S. Prescribing Information, revised 08/2026 (MOU-0012-USPI-20260827): Boxed Warning; sections 1, 2, 3, 4, 5, 6, 12.1 and 14.3, including Table 5 and its footnotes · Eli Lilly and Company · accessed
- 2.Eli Lilly and Company. Mounjaro Medication Guide, revised August 2026 (MOU-0010-MG-20260827): "What are the possible side effects of MOUNJARO?" and the birth control statement · Eli Lilly and Company · accessed
- 3.Novo Nordisk. Ozempic (semaglutide) injection, prescribing information, revised 05/2026 (DailyMed set id adec4fd2-6858-4c99-91d4-531f5f2a2d79, label version 20): Boxed Warning; sections 1, 2, 4, 5, 6, 8.3 and 12.1; Medication Guide (revised 01/2025) · Novo Nordisk · accessed
- 4.Novo Nordisk. Rybelsus and Ozempic (semaglutide) tablets, prescribing information, revised 01/2026 (DailyMed set id 27f15fac-7d98-4114-a2ec-92494a91da98, label version 14): Boxed Warning; sections 1 and 2 · Novo Nordisk · accessed
Telehealth prescribing rules differ by state. Read the state-by-state guide.
Majesta Health articles are written against primary sources (FDA labeling, NIH and CDC publications, state statutes) and each one passes a documented compliance review before publication. Where an article cites external sources, they are listed at the end of that article so you can check them yourself. No article currently carries an individual physician review; when a physician reviews an article, that page will show the reviewer's name, NPI and review date.
- Written against primary sources: FDA labeling and safety communications, NIH and CDC publications, state statutes and medical board rules
- Documented compliance review against FDA, FTC and LegitScript requirements before publication
- External sources, where an article cites them, are listed at the end of that article with links to the original documents
- Compounded medications are described as not FDA-approved as final products on every page that mentions them